DexCom (DXCM) is Reiterated by The Benchmark Company to Buy, Raises Price Target to $ 106

DexCom (DXCM) was Reiterated by The Benchmark Company to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 106 from a previous price target of $86 . The Benchmark Company advised their investors in a research report released on Aug 3, 2016.

On the company’s financial health, DexCom reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.12. The company had revenue of $137.30 million for the quarter, compared to analysts expectations of $132.54 million. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.

DexCom opened for trading at $92.49 and hit $92.86 on the upside on Tusday, eventually ending the session at $92.78, with a gain of 0.14% or 0.13 points. The heightened volatility saw the trading volume jump to 7,90,924 shares. Company has a market cap of $7,741 M.

In a different news, on Aug 2, 2016, Jeffrey Moy (SVP, Operations) sold 15,000 shares at $92.00 per share price. According to the SEC, on Jul 28, 2016, Andrew K Balo (EVP, Clinical and Regulatory) sold 5,000 shares at $88.14 per share price. On Jul 14, 2016, Kevin R Sayer (President & CEO) sold 7,000 shares at $79.92 per share price, according to the Form-4 filing with the securities and exchange commission.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.


Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.